Benzinga | Dec 29, 2021 06:04AM EST

Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $9.5

Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $12 to $9.5.